GlobeNewswire

Ovid Therapeutics Receives Orphan Drug Designation from the European Commission for OV101 for the Treatment of Angelman Syndrome

Share

NEW YORK, July 02, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that the European Commission (EC) has granted orphan drug designation (ODD) to OV101 (gaboxadol) for the treatment of Angelman syndrome based on the results of the Phase 2 STARS trial. OV101 is believed to be the only delta (δ)-selective GABAA receptor agonist in clinical development for the treatment of certain neurodevelopmental disorders, including Angelman syndrome.

“We are proud to be granted Orphan Drug Designation by the European Commission. This is another important step and further validates the potential of OV101 to be a meaningful treatment option for those living with Angelman syndrome around the world,” said Amit Rakhit, MD, MBA, Chief Medical Officer and Head of Research & Development at Ovid. “Today, there are no approved medicines specifically for Angelman syndrome. Ovid previously received Orphan Drug and Fast Track designation for OV101 from the U.S. Food and Drug Administration (FDA). We recently announced we have initiated the pivotal Phase 3 NEPTUNE trial in Angelman syndrome and have a clear route to registration, if positive.”

Dr. Rakhit continued, “It is believed that in the U.S. there are approximately 24,000 individuals with Angelman syndrome and a similar number in the European Union. OV101 is the only medicine currently in clinical development for Angelman syndrome. It’s our intent for OV101 to be the first medicine to be approved for this important and underserved community.”

About Orphan Drug Designation by the European Medicines Agency
About 30 million people in the European Union (EU) live with a rare disease. ODD in the EU is granted by the EC based on a positive opinion by the European Medicines Agency’s (EMA) Committee for Orphan Medicinal Products (COMP) to companies developing therapies to diagnose, prevent or treat a rare disease. To qualify for ODD, a potential medicine must target a life-threatening or chronically debilitating disease that affects no more than 5 in 10,000 persons in the EU. Additionally, the investigational medicinal product must either provide a significant benefit over existing therapies or provide a treatment for patients for whom existing therapies do not work or exist. The designation enables a company to benefit from incentives in the EU, such as reduced fees, centralized authorization and protection from competition for ten years once the medicine is approved for marketing.

About Angelman Syndrome
Angelman syndrome is a rare genetic disorder that is characterized by a variety of signs and symptoms. Characteristic features of this disorder include delayed development, intellectual disability, severe speech impairment, problems with movement and balance, seizures, sleep disorders and anxiety. The most common cause of Angelman syndrome is the loss of function of the gene that codes for ubiquitin protein ligase E3A (UBE3A), which plays a critical role in nerve cell communication, resulting in impaired tonic inhibition. Individuals with Angelman syndrome typically have normal lifespans but are unable to live independently, therefore, they require constant support from a network of specialists and caregivers. Angelman syndrome affects approximately 1 in 12,000 to 1 in 20,000 people globally.

There are no approved therapies for Angelman syndrome, and treatment primarily consists of behavioral interventions and pharmacologic management of symptoms.

Angelman syndrome is associated with a reduction in tonic inhibition, a function of the delta (δ)-selective GABAA receptor that allows a human brain to decipher excitatory and inhibitory neurological signals correctly without being overloaded. If tonic inhibition is reduced, the brain becomes inundated with signals and loses the ability to separate background noise from critical information.

About OV101
OV101 (gaboxadol) is believed to be the only delta (δ)-selective GABAA receptor agonist in development and the first investigational drug to specifically target the disruption of tonic inhibition, a central physiological process of the brain that is thought to be the underlying cause of certain neurodevelopmental disorders. OV101 has been demonstrated in laboratory studies and animal models to selectively activate the δ-subunit of GABAA receptors, which are found in the extrasynaptic space (outside of the synapse), and thereby impact neuronal activity through tonic inhibition.

Ovid is developing OV101 for the treatment of Angelman syndrome and Fragile X syndrome to potentially restore tonic inhibition and thereby address the core symptoms of these disorders. In both of these syndromes, the underlying pathophysiology includes disruption of the tonic inhibition modulated through the δ-subunit of GABAA receptors. In preclinical studies, it was observed that OV101 improved symptoms of Angelman syndrome and Fragile X syndrome. This compound has also previously been tested in over 4,000 patients (over 1,000 patient-years of exposure) and was observed to have favorable safety and bioavailability profiles. In 2018, Ovid announced the successful completion of its Phase 2 STARS trial of OV101 in adults and adolescents with Angelman syndrome. Ovid expects to enroll the first patients in the pivotal Phase 3 (NEPTUNE) clinical trial in children aged 4-12 years old with Angelman syndrome during the third quarter of 2019. In addition, Ovid is conducting a Phase 2 clinical trial (ROCKET) in Fragile X syndrome, with results expected around year-end 2019 or early 2020.

The FDA has granted Orphan Drug and Fast Track designations for OV101 for both the treatment of Angelman syndrome and Fragile X syndrome.

About Ovid Therapeutics
Ovid Therapeutics (NASDAQ: OVID) is a New York-based biopharmaceutical company using its BoldMedicine™ approach to develop medicines that transform the lives of patients with rare neurological disorders. Ovid has a broad pipeline of potential first-in-class medicines. The company’s most advanced investigational medicine, OV101 (gaboxadol), is currently in clinical development for the treatment of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 (soticlestat) in collaboration with Takeda Pharmaceutical Company Limited for the potential treatment of rare developmental and epileptic encephalopathies (DEE).

For more information on Ovid, please visit http://www.ovidrx.com/.

Forward-Looking Statements
This press release includes certain disclosures that contain “forward-looking statements,” including, without limitation, statements regarding advancing Ovid’s product candidates, progress, timing, scope and results of clinical trials for Ovid’s product candidates, and the reporting of clinical data regarding Ovid’s product candidates. You can identify forward-looking statements because they contain words such as “will,” “believes” and “expects.” Forward-looking statements are based on Ovid’s current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in Ovid’s filings with the Securities and Exchange Commission under the caption “Risk Factors”. Ovid assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

Contacts

Investors and Media:
Ovid Therapeutics Inc.
Investor Relations & Public Relations
irpr@ovidrx.com

Or

Investors:
Steve Klass
Burns McClellan, Inc.
sklass@burnsmc.com
(212) 213-0006

Media:
Jenn Gordon
Spectrum Science Communications
jgordon@spectrumscience.com
(202) 587-2580

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

FRO - Invitation to Q3 2019 Results Conference Call and Webcast19.11.2019 13:16:00 CETPress release

Frontline Ltd.’s preliminary third quarter 2019 results will be released on Wednesday November 27 2019, and a webcast and conference call will be held at 3:00 p.m. CET (9:00 a.m. U.S. Eastern Time). The results presentation will be available for download from the Investor Relations section at www.frontline.bm ahead of the conference call. In order to attend the conference call you may do one of the following: a. Webcast Go to the Investor Relations section at www.frontline.bm and follow the “Webcast” link. b. Conference Call Participant dial-in telephone numbers: Norway +47 2156 3162 Norway toll free 800 10392 UK +44 (0) 203 009 5710 UK Toll Free 0 800 376 7425 USA +1 917 720 0178 USA Toll Free 866 869 2321 Conference ID 5598374 Participants will be asked for their full name & Conference ID. A Q&A session will be held after the teleconference/webcast. Information on how to submit questions will be given at the beginning of the session. The presentation material which will be used in th

Oasmia offentliggör prospekt i samband med företrädesemission om cirka 399 MSEK samt uppdaterad information som återfinns i prospektet19.11.2019 13:00:00 CETPressemelding

EJ FÖR PUBLICERING, DISTRIBUTION ELLER OFFENTLIGGÖRANDE, DIREKT ELLER INDIREKT, HELT ELLER DELVIS, INOM ELLER TILL USA, AUSTRALIEN, HONGKONG, JAPAN, KANADA, NYA ZEELAND, SCHWEIZ, SINGAPORE, SYDAFRIKA ELLER NÅGON ANNAN JURISDIKTION DÄR SÅDAN PUBLICERING, DISTRIBUTION ELLER OFFENTLIGGÖRANDE SKULLE VARA I STRID MED GÄLLANDE REGLER ELLER KRÄVA YTTERLIGARE REGISTRERING ELLER ANDRA ÅTGÄRDER ÄN VAD SOM FÖLJER AV SVENSK RÄTT. Styrelsen i Oasmia Pharmaceutical AB (“Oasmia” eller ”Bolaget”) meddelande den 11 november 2019 om genomförandet av en nyemission av aktier med företrädesrätt för Oasmias befintliga aktieägare om cirka 399 MSEK ("Företrädesemissionen"). Bolaget har med anledning av Företrädesemissionen upprättat ett prospekt som idag godkänts och registrerats av Finansinspektionen. Offentliggörande av prospekt För fullständig information om Företrädesemissionen hänvisas till det prospekt som upprättats av Bolaget samt idag godkänts och registrerats av Finansinspektionen per dagens datum.

Oasmia publishes prospectus in connection with the rights issue of approximately SEK 399 million and updated information included in the prospectus19.11.2019 13:00:00 CETPress release

Not for release, publication or distribution, directly or indirectly, in or into Australia, Hong Kong, Japan, Canada, New Zealand, South Africa, Switzerland, Singapore, the United States or any other jurisdiction where such distribution of this press release would be subject to legal restrictions. This press release does not constitute an offer of any securities of Oasmia Pharmaceuticals AB (publ). See the section “IMPORTANT INFORMATION” below. The board of Oasmia Pharmaceutical AB (“Oasmia” or the “Company”) announced on 11 November 2019 to carry out a new issue of shares with preferential rights for Oasmia’s shareholders of approximately SEK 399 million (the “Rights Issue”). As a result of the Rights Issue, the Company has prepared a prospectus, which has been approved and registered by the Swedish Financial Supervisory Authority today. Publication of the prospectus For complete information on the Rights Issue, refer to the prospectus that has been prepared by Oasmia as well as appro

Medtronic Reports Second Quarter Financial Results19.11.2019 12:45:00 CETPress release

Revenue of $7.7 Billion Increased 3.0% Reported and 4.1% Organic GAAP Diluted EPS of $1.01; Non-GAAP Diluted EPS of $1.31 Cash Flow from Operations of $1.9 Billion Grew 61%; Free Cash Flow of $1.6 Billion Grew 66% Company Raises FY20 EPS Guidance DUBLIN, Nov. 19, 2019 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT) today announced financial results for its second quarter of fiscal year 2020, which ended October 25, 2019. The company reported second quarter worldwide revenue of $7.706 billion, an increase of 3.0 percent as reported or 4.1 percent on an organic basis, which adjusts for a $97 million negative impact from foreign currency and a $16 million contribution from the company’s acquisition of Titan Spine, which is reported in the Spine division in the Restorative Therapies Group. As reported, second quarter GAAP net income and diluted earnings per share (EPS) were $1.364 billion and $1.01, respectively. As detailed in the financial schedules included through the link at the end of t

Avenir LNG collaborates with Golar Power on developing small-scale LNG distribution in Brazil19.11.2019 12:00:00 CETPress release

London, Nov. 19, 2019 (GLOBE NEWSWIRE) -- Avenir LNG Limited (“Avenir”) wishes to announce that it will collaborate with Golar Power Limited (“Golar Power”) in developing the small-scale LNG market in Brazil. Avenir’s second 7,500 cbm LNG Carrier will be used to deliver LNG to various ports across Brazil upon delivery. The vessel will also offer ship-to-ship bunkering capability as part of Avenir’s global multi-nodal bunkering solution; adding to the Colombian, Mediterranean and Malaysian nodes which the company currently offers. Commenting on the collaboration with Golar Power, Andrew Pickering, Chief Executive Officer of Avenir LNG Limited, said, “This is another step in our strategy where we are working closely with a shareholder in leveraging its FSRU platform to develop small-scale LNG distribution and bunkering in key developing markets.” Commenting on the collaboration with Avenir LNG, Eduardo Antonello, Chief Executive Officer of Golar Power Limited, said, “Accessing small-scal